Biotech Values

[p3analyze]

>>I don't see patients in this trial used gemcitabine before<<

For the her2+ patients, especially those who previously responded to trastuzumab or lapatinib, it would be unthinkable for the oncologist to not try to use these HER2 drugs again, although you may be right they will simply switch to a different chemo combo regimen such as vinorelbine or gemcitabine with or without a taxane.